



Physician : NANCY GUBERTI
 ORDER: [REDACTED]
 CLIENT REF: [REDACTED]
 PATIENT: [REDACTED]
 ID: [REDACTED]
 SEX: [REDACTED]
 AGE: [REDACTED] DOB: [REDACTED]

CLIENT #: [REDACTED]

DNA Methylation Pathway Profile; Buccal Swab

GENE NAME / VARIATION	MUTATION NOT PRESENT	MUTATION(S) PRESENT	CALL	
SHMT/C1420T	-/-		G	Minus "-" represents no mutation Plus "+" represents a mutation "-/-" indicates there is no mutation "+/-" indicates there is one mutation "+/+" indicates there is a double mutation
AHCY/1	-/-		A	
AHCY/2	-/-		T	
AHCY/19	-/-		A	
MTHFR/C677T		+/-	Hetero	
MTHFR/A1298C	-/-		A	
MTHFR/3	-/-		C	
MTR/A2756G	-/-		A	
MTRR/A66G	-/-		A	
MTRR/H595Y		+/-	Hetero	
MTRR/K350A		+/-	Hetero	
MTRR/R415T	-/-		C	
MTRR/S257T	-/-		T	
MTRR/11	-/-		G	
BHMT/1	-/-		A	
BHMT/2		+/+	T	
BHMT/4		+/+	C	
BHMT/8		+/+	T	
CBS/C699T		+/-	Hetero	
CBS/A360A		+/-	Hetero	
CBS/N212N	-/-		C	
COMT/V158M	-/-		G	
COMT/H62H	-/-		C	
COMT/61	-/-		G	
SUOX/S370S	-/-		C	
VDR/Taq1	-/-		C	
VDR/Fok1	-/-		C	
MAOA		+/+	T	
NOS/D298E		+/-	Hetero	
ACAT/1-02		+/-	Hetero	

SPECIMEN DATA

Comments:

Date Collected: 04/18/2024

Date Received: 04/25/2024


Date Reported: 05/13/2024

Methodology: Real-time PCR technology for genotyping

This test was developed and its performance characteristics determined by Kashi Clinical Laboratories, Inc. The FDA has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Analyzed by Kashi Clinical Laboratories, Inc. 10101 SW Barbur Blvd., Suite 200, Portland, OR 97219

Methionine Metabolism Transmethylation & Transsulfuration Diagram



Introduction

Single nucleotide polymorphisms (SNPs) are DNA sequence variations, which may occur frequently in the population (at least one percent of the population.) They are different from disease mutations, which are very rare. Huntington's disease is an example of a disease mutation- if you inherit the altered gene, the disease will develop. Certain SNPs may be associated with particular health conditions, but they are not known to cause disease. The majority of SNPs in this report affect protein, enzyme or cell receptor structure or function. Some SNPs may have modest and subtle but true biological effects and have been correlated with health concerns or disease risk. Their abundance in the human genome as well as their higher frequencies in the human population have made them targets to help explain variation in risk of common diseases. Often multiple SNPs need to be present to alter metabolic or biochemical functions in the body. SNPs and gene expression may often be modified by epigenetic factors (diet, lifestyle, nutrition, toxicant exposures). The influence of a single SNP may vary widely: for example, a specific SNP in MTHFR may influence enzyme function from 30-60%. In contrast, the SNP with the greatest known effect on human height only accounts for 0.04 percent of height variations.

Individuals are classified as homozygous (+/+) for the variant if they carry 2 mutated alleles, heterozygous (+/-) if they carry only one mutated allele, and homozygous (-/-) for the wild type gene if they have no mutant alleles. This panel of SNPs provides information about many facets of health and wellness, with an emphasis on important biochemical processes such as methionine metabolism (see diagram on the preceding page), detoxification, hormone and neurotransmitter balance, and Vitamin D function.

It is emphasized that SNPs are not imminently associated with abnormal metabolism or disease conditions. The presence or absence of a reported SNP is not the sole determinant of physiological function; it is simply one potential contributing factor. The results presented in this report should be interpreted in context with symptoms, epigenetic factors and other laboratory findings.

MTHFR A1298C, C677T, 3

Pathways/biochemistry

Methylenetetrahydrofolate reductase (MTHFR) catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a co-substrate for remethylation of homocysteine to methionine. MTHFR helps pull homocysteine into the methionine synthesis cycle which facilitates maintenance of normal levels of homocysteine and essential methylation. MTHFR contains a bound flavin cofactor and uses NAD(P)H as the reducing agent.

Possible Health Implications

MTHFR enzyme activities may be reduced for homozygous (approximately 65%) and heterozygous C677T individuals (approximately 40%), respectively. The extent to which MTHFR C677T activity is actually

suppressed is dependent upon folate status.

Mutations in MTHFR may cause MTHFR deficiency (an autosomal recessive disorder) with a wide range of features including homocysteinuria, homocystinuria, developmental delay, severe mental retardation, perinatal death, psychiatric disturbances, and later-onset neurodegenerative disorders. Elevated levels of homocysteine can result in excess formation of S-adenosyl homocysteine (SAH) which is a very potent inhibitor of methyl transferase enzymes that are involved in methylation of DNA, RNA, neurotransmitters, phospholipids and other important molecules.

Mutations in MTHFR may increase risk of ischemic stroke, cardiovascular disease and folate-sensitive neural tube defects. There is accumulating evidence that C677T may be an independent risk factor for hypertension.

MTHFR/677 CT/TT genotypes are more frequently associated with symptoms of Autism Spectrum Disorder (ASD); the effect may be cumulative with MTHFR/A1298C polymorphism. There is growing evidence that the MTHFR/A1298C homozygous mutation may be a genetic risk factor for male infertility. Studies indicate that hyperhomocysteinemia and the TT genotype may contribute to mood disorders.

Genotypic/Phenotypic expression

The C677T homozygous mutation is associated with decreased MTHFR activity and mild hyperhomocysteinemia, especially in the absence of adequate intake of folate. Low folate intake affects individuals with the 677TT genotype to a greater extent than those with the 677CC/CT genotypes. Those with coronary artery disease (about 17%), arterial disease (about 19%) and venous thromboembolism (about 11%) are more likely to carry the C677T homozygous (TT) mutation. MTHFR mutations in conjunction with genetic thrombophilic factors markedly increases risk for venous thrombosis.

The A1298C mutation is not associated with hyperhomocysteinemia, unless present in conjunction with the C677T mutation. The cumulative effect of the two mutations has been associated with decreased MTHFR activity and hyperhomocysteinemia. SHMT/ C1420T (homozygous) with MTHFR C677T polymorphisms may have a cumulative effect on increased cardiovascular risk, and increased homocysteine levels.

MTHFR may demonstrate cumulative effects with MTR, MTRR, AHCY or CBS polymorphisms. Studies indicate that MTHFR C677T may interact with environment and lifestyle to influence age of menarche and menopause for women.

There is mounting evidence that, especially within the folate and methylation pathways, multiple SNPs in multiple genes (haplotypes) may be necessary to alter metabolism or change health outcomes. In general, homozygotes are more influenced by SNPs than heterozygotes.

How to optimize the phenotype

Support methylation pathways and methionine metabolism with adequate B-12 (methyl B-12), folate (5-methylTHF), betaine and B vitamins (B-6, riboflavin). Monitor methionine metabolism and the Methylation index (DDI Methylation Profile).

References

www.uniprot.org [Accessed 10/31/2012]

Sibani S et al. Characterization of six novel mutations in the methylenetetrahydrofolate reductase

(MTHFR) gene in patients with homocystinuria. *Hum. Mutat.* 15:280-287(2000)

Kluijtmans L et al. Identification of four novel mutations in severe methylenetetrahydrofolate reductase deficiency. *Eur. J. Hum. Genet.* 6:257-265(1998)

Goyette P et al. Severe and mild mutations in cis for the methylenetetrahydrofolate reductase (MTHFR) gene, and description of five novel mutations in MTHFR." *Am. J. Hum. Genet.* 59:1268-1275(1996).

Goyette P et al. Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/phenotype correlations in severe methylenetetrahydrofolate reductase deficiency. *Am. J. Hum. Genet.* 56:1052-1059(1995).

Arruda V et al. (1997). The mutation Ala677-->Val in the methylene tetrahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. *Thromb Haemost* 77: 818-821.

Cattaneo M. (1999). Hyperhomocysteinemia, atherosclerosis and thrombosis. *Thromb Haemost* 81:165-176.

Frost P et al. (1995). A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. *Nat Genet* 10:111-113.

Jacques P et al. (1996). Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. *Circulation* 93:7-9.

van der Put NM et al. (1998) A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects(c) *Am J Hum Genet* 62:1044-1051.

Szczeklik A et al. (2001). Mutation A1298C of methylenetetrahydrofolate reductase: risk for early coronary disease not associated with hyperhomocysteinemia. *Am J Med Genet* 101:36-39.

Eloualid, Abdemajid, et al. (2012) Association of the MTHFR A1298C Variant with Unexplained Severe Male Infertility. *PLoS One.* 2012; 7(3): e34111. Published online 2012 March 23. doi: 10.1371/journal.pone.0034111 . Accessed 12/12/12
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3311580/>

OMIM Online Mendelian Inheritance in Man. MTHFR <http://omim.org/> Accessed 16 July 2013

MTRR A66G/H595Y/K350A/R415T/S257T/11 (methionine synthase reductase)

Pathways/biochemistry

Methionine synthase reductase (MTRR) is one of two enzymes involved in the regeneration of methionine (with MTR) from homocysteine. MTRR regenerates methionine synthase (MTR) via a reductive methylation reaction that uses S-adenosylmethionine (donor) and NADPH. MTRR supports methionine synthase (MTR) activity by "recycling" vitamin B-12. Studies indicate that MTRR may also be required as a molecular chaperone for proper methionine synthase (MTR) function.

Possible Health Implications

MTRR/A66G produces an MTRR enzyme with a lower affinity for MTR and some studies have found it to be associated with homocysteine levels; further studies have shown that MTR requires MTRR to function properly. The 66AG/GG SNPs are also associated with increased micronucleation, a marker for chromosome damage and developmental delays.

MTRR/66 AA is considered a risk factor for folate-related neural tube defects and increased risk of Down's syndrome, specifically as a maternal risk factor when homocystiene levels are high. MTRR/66 AA is associated with a higher rate of micronucleation, a marker for cell damage and developmental delays. The rate of micronucleation increases with a history of smoking. MTRR/66 AA is more frequently associated with symptoms of Autism Spectrum Disorder(ASD).

MTRR/66GG is associated with male infertility (as are MTHFR and MTR). Polymorphisms in MTRR- /66/AG/GG and /H595Y-have been associated with the risk of cancers (breast, colon, prostate, pancreatic); the 66GG SNP appears to reduce the risk of acute lymphoblastic leukemia and, Alzheimer disease.

MTRR/66 AG/GG is associated with an increased risk of gastric cancers -this association is currently only documented for Asian populations (Korean); the risk increases further with obesity. MTRR/A66G polymorphism may reduce risk for autism.

There is mounting evidence that, especially within the folate and methylation pathways, multiple SNPs in multiple genes (haplotypes) and low folate or B-vitamin status are necessary to alter metabolism or change health outcomes. MTRR polymorphisms may have cumulative effects with MTHFR/C677T, MTR, AHCY or CBS polymorphisms.

The clinical significance of MTRR polymorphisms /K350A/, R415T, /S257T, and /11 is currently unknown; research is ongoing.

In general, homozygotes are more influenced by SNPs than heterozygotes.

How to optimize the phenotype

Provide adequate B-12, folate and nutritional support for methylation pathways. Hydroxycobalamin may be the preferred form of B-12 for this SNP. Minimize cancer risks with lifestyle interventions.

References

- <http://www.uniprot.org/uniprot/Q9UBK8> MTRR_HUMAN. Accessed 11/09/2012
- Yoo, Jae-Young, et al. (2012) Association Study between Folate Pathway Gene Single Nucleotide Polymorphisms and Gastric Cancer in Koreans. *Genomics Inform.* Sep;10(3):184-193. Accessed 11/09/2012
- [http://synapse.koreamed.org/search.php\(c\)where=aview&id=10.5808/GI.2012.10.3.184&code=0117GNI&vmode=FULL](http://synapse.koreamed.org/search.php(c)where=aview&id=10.5808/GI.2012.10.3.184&code=0117GNI&vmode=FULL)
- Dutta, S. et al. (2011) Importance of gene variants and co-factors of folate metabolic pathway in the etiology of idiopathic intellectual disability. *Nutr Neurosci.* Sep;14(5):202-9. Accessed 11/12/2012 <http://carcin.oxfordjournals.org/content/28/3/625.abstract>
- Lee, Han-Chul, et al. (2006) Association study of four polymorphisms in three folate-related enzyme genes with non-obstructive male infertility. *Hum. Reprod.* 21 (12): 3162-3170. doi: 10.1093/humrep/del280. Accessed 11/12/2012 <http://humrep.oxfordjournals.org/content/21/12/3162.long>
- Gemmati D. et al. (2004) Common gene polymorphisms in the metabolic folate and methylation pathway and the risk of acute lymphoblastic leukemia and non-Hodgkin's lymphoma in adults. *Cancer Epidemiol Biomarkers Prev.* May;13(5):787-94. Accessed 11/12/2012 <http://www.ncbi.nlm.nih.gov/pubmed/15159311>
- Ishikawa, Hitoshi ; Ishikawa, Takashi ; Miyatsu, Yu ; Kurihara, Kazuo ; Fukao, Akira ; Yokoyama, Kazuhito. (2006) A polymorphism of the methionine synthase reductase gene increases chromosomal damage in peripheral lymphocytes in smokers. *Mutation research. Fundamental and molecular mechanisms of mutagenesis.* 2006, vol. 599, no1-2, pp. 135-143. Accessed 11/12/2012 [http://cat.inist.fr/\(c\)aModele=afficheN&cpsid=17978661](http://cat.inist.fr/(c)aModele=afficheN&cpsid=17978661)

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2610366/pdf/nihms68264.pdf>
<http://www.uniprot.org/uniprot/Q9UBK8> MTRR_HUMAN. Accessed 11/12/2012
OMIM Online Mendelian Inheritance in Man. MTRR <http://omim.org/> Accessed 16 July 2013

BHMT 1,2,3,4 (betaine-homocysteine methyltransferase)

Pathways/biochemistry

Betaine-homocysteine methyltransferase (BHMT) catalyzes the transfer of a methyl group from betaine to homocysteine to produce methionine and dimethylglycine. This is commonly referred to as the "short route" in the regeneration of methionine from homocysteine. The "long route" requires folate (MTHFR) and B-12 (MTR and MTRR). BHMT and its polymorphisms are involved in the regulation and metabolism of homocysteine. The BHMT pathway is folate-independent, although levels of folate, choline, and dimethylglycine (DMG) are predictive for plasma betaine levels. DMG inhibits BHMT by product inhibition, but does not affect the BHMT2 variant. The enzyme is found almost exclusively in liver and kidney tissues; the reaction is involved in choline oxidation as well as the methylation of homocysteine. The BHMT-2 polymorphism product is rapidly degraded unless it is bound to BHMT and is stabilized by homocysteine to become a functional product. BHMT2 cannot use betaine, rather it converts homocysteine to methionine using S-methylmethionine as a methyl donor. Methionine levels regulate BHMT2 activity by product inhibition.

Possible Health Implications

BHMT and its polymorphisms are involved in the regulation and metabolism of homocysteine. BHMT has been reported to protect the liver from homocysteine-induced injury. Elevated levels of homocysteine are a known risk factor for vascular disease and neural tube defects. Elevated circulating homocysteine levels are also being studied as a possible risk factor for osteoporosis, dementia, and complications of pregnancy. Animal studies have shown BHMT2 to be protective, with adequate nutrition, against acetaminophen-induced liver toxicity.

Preliminary research indicates that BHMT1 may have some function in immune response and reactivity.

Genotypic/Phenotypic expression

Polymorphisms will likely be present with altered elevated homocysteine levels.
In general, homozygotes are more influenced by SNPs than heterozygotes.

How to optimize the phenotype

Consider the DDI Methylation Profile to assess the components of the methylation pathway. Zinc-dependent BHMT requires adequate levels of betaine to function optimally. Support the methionine synthase dependent methylation pathway ("Long route") with adequate B-12 and folate.

References

<http://www.uniprot.org/uniprot/Q93088> BHMT1_HUMAN. Accessed 10/30/2012
<http://www.uniprot.org/uniprot/Q9H2M3> BHMT2_HUMAN. Accessed 11/12/2012
Feng, Qiping et al. (2011) Betaine-homocysteine methyltransferase: human liver genotype-phenotype correlation. *Mol Genet Metab.* February; 102(2): 126-133. Accessed 11/01/2012.

Li, Fang et al. (2008) Human Betaine-Homocysteine Methyltransferase (BHMT) and BHMT2: Common Gene Sequence Variation and Functional Characterization. *Mol Genet Metab.* July; 94(3): 326-335. Accessed 11/01/2012 <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515933/>
Szegedi SS, Castro CC, Koutmos M, Garrow TA. (2008) Betaine-homocysteine S-methyltransferase-2 is an S-methylmethionine-homocysteine methyltransferase. *J Biol Chem.* Apr 4;283(14):8939-45. Accessed 11/02/2012 <http://www.ncbi.nlm.nih.gov/pubmed/18230605>
Liu, Hohg-Hsing et al. (2010) An integrative genomic analysis identifies Bhmt2 as a diet-dependent genetic factor protecting against acetaminophen-induced liver toxicity. *Genome Res.* January; 20(1): 28-35 Accessed 11/02/2012 <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2798828/>

We have never put a color diagram in commentaries. This is useful but perhaps we can re-do in black and white.

CBS /C699T/A360A/N212N (Cystathionine beta-synthase)

Pathways/biochemistry

CBS catalyzes the first irreversible step of the transsulfuration pathway. CBS catalyzes the vitamin B6-dependent reaction between serine and homocysteine, producing cystathionine enroute to taurine, cysteine, sulfate and glutathione. CBS function is influenced by betaine levels via re-methylation of homocysteine. Possible Health Implications

Some defects in CBS are responsible for homocystinuria and altered sulfur metabolism. The SNPs evaluated are found in various tissues and have different functions in the body. Mutations in CBS may alter homocysteine levels and risk for CVD; there may also be changes in cancer risks. Health implications are related to the individual SNPs.

CBS/699TT (homozygous) is significantly associated with lower fasting total homocysteine levels and is associated with a decreased risk of coronary artery disease.

CBS/A360A is associated with a reduced risk of breast cancer. Paradoxically, it may be associated with an increased risk of lung cancer - current research indicates that CBS/A360A serves as a marker for the yet-unidentified CBS SNP responsible for the increased risk.

CBS/N212N is currently under investigation for an association with Ehlers-Danlos syndrome and other collagen disorders.

Genotypic/Phenotypic expression

In general, homozygotes are more influenced by SNPs than heterozygotes.

How to optimize the phenotype

CBS function is influenced by B-6, betaine and folate status; may have cumulative effects with MTHFR

References

<http://www.uniprot.org/uniprot/P35520> Cystathionine beta-synthase. Accessed 11/02/2012
Kraus, Jan P. et al. (1998) The Human Cystathionine â-Synthase (CBS) Gene: Complete Sequence,

Alternative Splicing, and Polymorphisms. *Genomics*. Volume 52, Issue 3, 15 September 1998, Pages 312-324. Accessed 11/02/2012 <http://www.sciencedirect.com/science/article/pii/S0888754398954374>

Stevens, Victoria L.; McCullough, Marjorie L.; Pavluck, Alexandre L.; Talbot, Jeffrey T.; Feigelson, Heather S.; Thun, Michael J. and Calle, Eugenia E. (2007) Association of Polymorphisms in One-Carbon Metabolism Genes and Postmenopausal Breast Cancer Incidence *Cancer Epidemiol Biomarkers Prev*. June 2007 16; 1140. Accessed 11/02/2012 <http://cebp.aacrjournals.org/content/16/6/1140.long>

D'Angelo, Armando; Mazzola, Giuseppina; Fermo, Isabella. (2003) Gene-Gene and Gene-Environment Interactions in Mild Hyperhomocysteinemia. *Pathophysiol Haemost Thromb* 2003/2004 33: 337-341. Accessed 11/02/2012 [http://content.karger.com/produktedb/produkte.asp\(c\)typ=pdf&file=PHT20030335_6337](http://content.karger.com/produktedb/produkte.asp(c)typ=pdf&file=PHT20030335_6337)

Kery, V., Poneleit, L., Meyer, J. D., Manning, M. C., Kraus, J. P. Binding of pyridoxal 5-prime-phosphate to the heme protein human cystathionine beta-synthase. *Biochemistry* 38: 2716-2724, 1999.

Christopher SA, Melnyk S, James SJ, Kruger WD. S-adenosylhomocysteine, but not homocysteine, is toxic to yeast lacking cystathionine beta-synthase. *Mol Genet Metab*. 2002 Apr;75(4):335-43.

Scott, John W. et al. (2004) CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations. *J. Clin. Invest*. 113:274-284 (2004). doi:10.1172/JCI200419874

Summers et al. (2008) Influence of the cystathionine β -synthase 844ins68 and methylenetetrahydrofolate reductase 677C>T polymorphisms on folate and homocysteine concentrations. *European Journal of Human Genetics* (2008) 16, 1010-1013; doi:10.1038/ejhg.2008.69; published online 9 April 2008

Anthony J. Barak, Harriet C. Beckenhauer*, Mark E. Mailliard, Kusum K. Kharbanda* and Dean J. Tumar (2003) Betaine Lowers Elevated S-Adenosylhomocysteine Levels in Hepatocytes from Ethanol-Fed Rats. *J. Nutr*. September 1, 2003 vol. 133 no. 9 2845-2848

Kruger, W.D. et al. (2000) Polymorphisms in the CBS gene associated with decreased risk of coronary artery disease and increased responsiveness to total homocysteine lowering by folic acid. *Mol Genet Metab*. May;70(1):53-60. Accessed 11/02/2012 [http://www.ncbi.nlm.nih.gov/pubmed/10833331\(c\)dopt=Abstract](http://www.ncbi.nlm.nih.gov/pubmed/10833331(c)dopt=Abstract)

MAO A/R297R (monoamine oxidase type A)

Pathways/biochemistry

Monoamine oxidase type A (MAO A) catalyzes the oxidative deamination of biogenic, dietary and xenobiotic amines and, degrades the neurotransmitters serotonin, dopamine, epinephrine, and norepinephrine. MAO A has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAO enzymes also deaminate dietary amines, such as tyramine.

Possible Health Implications

MAO A preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (serotonin), norepinephrine and epinephrine. Serotonin is involved with mood, and aberrant serotonin metabolism is associated with depression, aggression, anxiety, and OCD behavior. Impairment in the central dopamine pathways and metabolism has been suggested as a factor in the pathogenesis of restless legs syndrome (RLS).

Several studies indicate a genetic influence on stress-related disorders. There is evidence that a functional polymorphism in MAO A may influence adult response to childhood abuse or trauma. The association between childhood maltreatment, aggression and mental health problems is significantly stronger in males with the genotype conferring low (TT) vs. high (GG) MAOA activity. Females with childhood trauma and high

MAO A (GG) activity may be more aggressive in conjunction with sad mood.

Studies indicate that the high-activity MAOA (GG) genotypes may have less severe autistic symptoms or behaviors.

Genotypic/Phenotypic expression

The G allele encodes for the higher activity form of the enzyme. GT/GG phenotypes have significantly decreased placebo responses. The effects may be cumulative with COMT H62H polymorphisms. MAO A is inherited with the X chromosome and is considered a dependent trait; it may not show standard inheritance characteristics in males. Since the X chromosome in males can only come from the mother, there is no paternal contribution to the genotype. For females, since one X chromosome is inherited from each parent, the genetics tend to reflect the MAO A status of both parents.

How to optimize the phenotype

Monitor clinical indications of abnormal serotonin metabolism and plasma tryptophan. Individuals with genotypic variations may not respond to therapies that rely on placebo effect, and may need pharmaceutical support for mood disorders.

References

www.uniprot.org [Accessed 10/30/2012]

Kim-Cohen, J.; A Caspi, A.; A Taylor, A.; Williams, B.; Newcombe, R.; Craig, I.W.; and Moffitt, T.E. (2006) MAOA, maltreatment, and gene-environment interaction predicting children's mental health: new evidence and a meta-analysis. *Molecular Psychiatry* (2006) 11, 903-913. doi:10.1038/sj.mp.4001851; published online 27 June 2006. Accessed 12/10/2012

<http://www.nature.com/mp/journal/v11/n10/full/4001851a.html>

Tipton, K.F. (1997) Monoamine oxidase inhibitors and pressor response to dietary amines. *Vopr Med Khim.* 1997 Nov-Dec;43(6):494-503. Accessed 12/21/2012

<http://www.ncbi.nlm.nih.gov/pubmed/9503566>

Verhoeven FE, Booij L, Kruijt AW, Cerit H, Antypa N, Does W. (2012) The effects of MAOA genotype, childhood trauma, and sex on trait and state-dependent aggression. *Brain Behav.* 2012 Nov;2(6):806-13. doi: 10.1002/brb3.96. Epub 2012 Oct 5. Accessed 12/10/2012

<http://www.ncbi.nlm.nih.gov/pubmed/23170243>

Xu Z, Zhang Z, Shi Y, Pu M, Yuan Y, Zhang X, Li L. (2011) Influence and interaction of genetic polymorphisms in catecholamine neurotransmitter systems and early life stress on antidepressant drug response. *J Affect Disord.* 2011 Sep;133(1-2):165-73. Epub 2011 Jun 16. Accessed 12/10/2012

[http://www.ncbi.nlm.nih.gov/pubmed/21680027\(c\)dopt=Abstract](http://www.ncbi.nlm.nih.gov/pubmed/21680027(c)dopt=Abstract)

Leuchter AF, McCracken JT, Hunter AM, Cook IA, Alpert JE. (2009) Monoamine oxidase a and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder. *J Clin Psychopharmacol.* 2009 Aug;29(4):372-7. Accessed 12/10/2012

[http://www.ncbi.nlm.nih.gov/pubmed/19593178\(c\)dopt=Abstract](http://www.ncbi.nlm.nih.gov/pubmed/19593178(c)dopt=Abstract)

OMIM Online Mendelian Inheritance in Man. MOA <http://www.omim.org/> accessed 16 July 2013

Cohen, I. L., Liu, X., Schutz, C., White, B. N., Jenkins, E. C., Brown, W. T., Holden, J. J. A. Association of autism severity with a monoamine oxidase A functional polymorphism. *Clin. Genet.* 64: 190-197, 2003.

ENOS (NOS3)/D298E (endothelial nitric oxide synthase)

Pathways/biochemistry

Endothelial nitric oxide synthase (ENOS/NOS3) synthesizes nitric oxide (NO) from arginine. NO mediates smooth muscle relaxation and angiogenesis and, promotes blood clotting via platelet activation. Endothelial NOS3 is calcium dependent. Cobalamin (B-12) is required for NOS regulation, and ENOS/NOS3 polymorphisms may be influenced by omega-3 fatty acid status and oxidative stress. ENOS/NOS3 serves as a substrate for other enzymes involved in glucose metabolism, apoptosis, cell proliferation, transcription and cell migration.

Possible Health Implications

There have been many studies regarding this polymorphism and a large number of controversial reports have been published. These inconsistent findings might be explained in part by the genetic and environmental differences among populations. It is also possible that ENOS/NOS3 SNPs only contribute to atherosclerosis through interactions with other genes. The NO pathway may play a role in the expression of congenital urea cycle disorders.

SNPs in both NOS3 and apolipoprotein E are associated with increased risk of atherosclerosis. When present with coronary artery disease (CAD) and hyperhomocysteinuria, the NOS3 /D298E SNP increases the severity of disease. NOS3/D289E is associated with hypertension, changes in coronary artery vasodilation, post-stroke dementia risk, increased oxidative stress (due to air particulate pollution), and increased risk of Left Ventricular Hypertrophy. In general, homozygotes are more influenced by SNPs than heterozygotes.

Tibolone, (a synthetic steroid hormone used in post-menopausal women for hormone replacement therapy), and its metabolites, has been shown to activate ENOS/NOS3 and NO synthesis.

Genotypic/Phenotypic expression

Homozygous expression may be more common in those of Asian and Caucasian descent.

In women of Japanese descent NOS3/D298E is an independent risk factor for hypertension during pregnancy. Estrogen or hormone replacements may also play a role in gene regulation and expression.

How to optimize the phenotype

Endothelial NOS is calcium dependent. Vitamin B-12 is required for NOS regulation, and NOS3/D298E polymorphisms may be influenced by poor omega-3 fatty acid status and oxidative stress. Smoking status and omega-3 fatty acid status may play a role in the phenotypic expression of the NOS polymorphism. Estrogen or hormone replacements may also play a role in gene regulation and expression.

References

<http://www.uniprot.org/uniprot/P29474> NOS3_HUMAN. Accessed 11/05/2012

Villanueva, Cleva and Giulivi, Cecilia. (2010) Subcellular and cellular locations of nitric-oxide synthase isoforms as determinants of health and disease. *Free Radic Biol Med.* August 1; 49(3): 307-316.

Accessed 11/05/2012 <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2900489/>

Chang, Kiyuk et al. (2003) The Glu298Asp polymorphism in the endothelial nitric oxide synthase gene

is strongly associated with coronary spasm. *Coronary Artery Disease*: June 2003 - Volume 14 - Issue 4 - p 293-299. Accessed 11/05/2012 http://journals.lww.com/coronary-artery/Abstract/2003/06000/The_Glu298Asp_polymorphism_in_the_endothelial.4.aspx

Tu, Yuan-chao Tu; Ding, Hu; Wang, Xiao-jing; Xu, Yu-jun; Zhang, Lan; Huang, Cong-xin and Wang, Dao-wen. (2010) Exploring epistatic relationships of NO biosynthesis pathway genes in susceptibility to CHD. *Acta Pharmacologica Sinica* (2010) 31: 874-880; doi: 10.1038/aps.2010.68; published online 28 June 2012. Accessed 11/05/2012 <http://www.nature.com/aps/journal/v31/n7/full/aps201068a.html>

Casas, Juan P.; Cavalleri, Gianpiero L.; Bautista, Leonelo E.; Smeeth, Liam; Humphries, Steve E. and Hingorani, Aron D. (2006) Endothelial Nitric Oxide Synthase Gene Polymorphisms and Cardiovascular Disease: A HuGE Review. *Am. J. Epidemiol.* (15 November 2006) 164 (10): 921-935 Accessed 11/05/2012 <http://aje.oxfordjournals.org/content/164/10/921.full>

Morris, Christopher M. et al. (2011) NOS3 gene rs1799983 polymorphism and incident dementia in 2012 elderly stroke survivors. *Neurobiology of Aging* Volume 32, Issue 3, Pages 554.e1-554.e6, March 2011. Accessed 11/05/ [http://www.neurobiologyofaging.org/article/S0197-4580\(10\)00277-0/abstract](http://www.neurobiologyofaging.org/article/S0197-4580(10)00277-0/abstract)

Xin, Ying et al. (2009) A common variant of the eNOS gene (E298D) is an independent risk factor for left ventricular hypertrophy in human essential hypertension. *Clinical Science* 117, (67-73). Accessed 11/05/2012 <http://www.clinsci.org/cs/117/cs1170067.htm>

Wheatley, Carmen. (2007) The return of the Scarlet Pimpernel: cobalamin in inflammation II - cobalamins can both selectively promote all three nitric oxide synthases (NOS), particularly iNOS and eNOS, and, as needed, selectively inhibit iNOS and nNOS *J Nutr Environ Med.* 2007 Sep-Dec; 16(3-4): 181-211. Accessed 11/05/2012 <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2556189/>

Nagasaka, Hironori et al. (2009) Evaluation of endogenous nitric oxide synthesis in congenital urea cycle enzyme defects. *Metabolism* Volume 58, Issue 3, March 2009, Pages 278-282. Accessed 11/05/2012 <http://www.sciencedirect.com/science/article/pii/S0026049508003624>

Kobashi, Gen. Genetic and Environmental Factors Associated with the Development of Hypertension in Pregnancy. *Journal of Epidemiology* Vol. 16 (2006) No.1, P 1-8. Accessed 11/05/2012 https://www.jstage.jst.go.jp/article/jea/16/1/16_1_1/_article

OMIM Online Mendelian Inheritance in Man. NOS3 <http://omim.org/> Accessed 16 July 2013

Simoncini, T., Mannella, P., Fornari, L., Caruso, A., Varone, G., Garibaldi, S., Genazzani, A. R. Tibolone activates nitric oxide synthesis in human endothelial cells. *J. Clin. Endocr. Metab.* 89: 4594-4600, 2004

ACAT /1 (acetyl coenzyme A acetyltransferase)

Pathways/biochemistry

ACAT is an enzyme found both in the cytoplasm (ACAT/2) and the mitochondria (ACAT/1). ACAT/1 is found in all tissues except intestinal tissue; ACAT/2 is found primarily in intestinal tissues. The ACAT/1 enzyme (mitochondrial) plays an important role beta-oxidation of fatty acids and protein metabolism; it is a step in the metabolic pathway for the amino acid isoleucine, and contributes to cellular energy production. ACAT/1 also completes ketone metabolism, synthesizing acetyl-Co-A for energy production.

ACAT/2 encodes a similar enzyme in the cytosol which is involved in the early steps of cholesterol biosynthesis and lipid metabolism.

Possible Health Implications

Polymorphism in ACAT/1 may increase the level of organic acids in the blood. Ketoacidosis may result from increased organic acidemia and may damage body tissues and organs, such as the nervous system. Mutations in ACAT/1 may cause the condition beta-ketothiolase deficiency. ACAT/1 may also be involved in foam cell formation and atherosclerosis.

Genotypic/Phenotypic expression

Based solely on the mutation, ACAT1 may function poorly or not at all. However, published research indicates that genotype alone does not predict expression of the disorder; most patients develop normally and are able to manage symptoms. In general, homozygotes are more influenced by SNPs than heterozygotes.

How to optimize the phenotype

Monitor levels of organic acids, ketones, cholesterol and manage accordingly. Monitor plasma lipoproteins, especially oxidized low density lipoproteins (LDL), small dense LDL and apolipoproteins B.

References

<http://www.uniprot.org/uniprot/Q9BWD1> THIC_HUMAN. Accessed 11/06/2012

<http://www.uniprot.org/uniprot/P24752> THIL_HUMAN. Accessed 11/06/2012

Genetics Home Reference. ACAT1. Accessed 11/06/2012 <http://ghr.nlm.nih.gov/gene/ACAT1>

Katsuren, Keisuke et al. (2001) Structure of the human acyl-CoA:cholesterol acyltransferase-2 (ACAT-2) gene and its relation to dyslipidemia *Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids* Volume 1531, Issue 3, 30 April 2001, Pages 230-240. Accessed 11/06/2012

<http://www.sciencedirect.com/science/article/pii/S1388198101001068>

Fukao, Toshiyuki; Scriver, Charles R.; Kondo, Naomi. (2001) The Clinical Phenotype and Outcome of Mitochondrial Acetoacetyl-CoA Thiolase Deficiency (â-Ketothiolase or T2 Deficiency) in 26 Enzymatically Proved and Mutation-Defined Patients. *Molecular Genetics and Metabolism* Volume 72, Issue 2, February, Pages 109-114. Accessed 11/06/2012

<http://www.sciencedirect.com/science/article/pii/S1096719200931135>